Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06669 先瑞達醫療-B
ACOTEC-B
Listing Date2021/08/24
Listing Price23.800
 
Quote
  • 11.500 +0.100 (+0.877%)    Sink Below Listing Price
  • 15-min delayed, last update: 07/12/2021 17:05
Subscription Result
  • Subscription Rate
    654.51x
  • Guarantee One Lot Size
    200 lot
  • One Lot Success Rate
    3%
COMPANY PROFILE

Acotec Scientific Holdings is an innovative medical device company in China focusing on providing “leave nothing behind” treatment solutions for vascular diseases. It has developed a suite of interventional medical devices, notably in the fields of drug-coated balloons (DCB) and thrombus aspiration catheters.

Its first peripheral DCB product had a dominating market share of approximately 86.9% in the peripheral DCB market in China in terms of revenue generated in 2020. Its second DCB product also obtained the NMPA approval in December 2020, making it the world’s first below-the-knee (BTK) DCB product receiving regulatory approval based on multi-center randomized controlled clinical trial results.

Its core product is a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach. Another core product is AcoArt TulipTM & LitosTM. These products had also launched in eleven other countries such as Germany, Italy and Switzerland.

The Group is also in the process of developing a comprehensive product pipeline, with 24 product candidates in various stages of development. It owned eight registered patents and had two pending patent applications in relation to its Core Products.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot1000
GLOBAL OFFERING
No. of Offer Shares68.63M shares
No. of International Offer Shares61.77M shares
No. of HK Offer Shares6.86M shares
Offer Price$22.20 - $23.80
Stock Code6669
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, China Merchants Securities (HK) Co., Limited, Morgan Stanley Asia Limited, Valuable Capital Limited
TIME TABLE
Application PeriodAug 12 (Thu) - noon, Aug 17 (Tue)
Price Determination DateAug 17 (Tue)
Result Announcement DateOn or before Aug 23 (Mon)
Result Announcement DateOn or before Aug 23 (Mon)
Dealings in Shares commence onAug 24, 2021. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$22.20 - $23.80
Capitalization6.96B - 7.46B
NAV / share ($)$3.68 - $4.05 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 23.00, the net proceeds raised would be HKD 1.47B, of which
32% : research and development and commercialization Core Products
23% : research and development and commercialization the remaining products in current product pipeline
24% : expansion of product portfolio through in-house research and development, collaborations, mergers and acquisitions
7% : strengthening manufacturing capabilities
8% : working capital and general corporate purposes
6% : repayment of the Loan
RELATED STOCK COMPARISON
Code Name Nominal Change %Change
02160CARDIOFLOW-Bup4.3200.0300.699%
02500VENUS MEDTECH-Bup26.3500.8503.333%
06669ACOTEC-Bup11.5000.1000.877%
09996PEIJIA-Bunchange15.2600.0000.000%
15-min delayed, last updated: 07/12/2021 17:05
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.